BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10999747)

  • 1. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R; Takano T; Sato S; Yajima A
    Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
    Ugurel S; Rappl G; Tilgen W; Reinhold U
    Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma.
    Ma Y; Ye F; Lv W; Cheng Q; Chen H; Xie X
    Eur J Obstet Gynecol Reprod Biol; 2008 Jun; 138(2):204-11. PubMed ID: 17826886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
    Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
    Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
    Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
    Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
    Pignataro L; Arisi E; Sambataro G; Corsi MM
    J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
    Lim SC
    Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.
    Midis GP; Shen Y; Owen-Schaub LB
    Cancer Res; 1996 Sep; 56(17):3870-4. PubMed ID: 8752148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
    Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
    Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis.
    Baldwin RL; Tran H; Karlan BY
    Gynecol Oncol; 1999 Aug; 74(2):265-71. PubMed ID: 10419743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y; Fuse H; Masai M
    Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating soluble Fas in patients with breast cancer.
    Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
    World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
    Tagami A; Ohnishi H; Hughes RD
    Hepatogastroenterology; 2003; 50(51):742-5. PubMed ID: 12828076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.